Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Biocytogen Pharmaceuticals has entered into a strategic collaboration with SOTIO Biotech to develop next-generation antibody-drug conjugates for solid tumor treatment, involving Biocytogen’s RenLite platform and SOTIO’s ADC platform. The agreement could yield Biocytogen up to $325.5 million in upfront and milestone payments, plus royalties on net sales. While SOTIO will handle the development, manufacturing, and commercialization, the companies will work jointly in the research phase.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.
